Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss DrugZacks Investment Research • 01/09/25
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesityPRNewsWire • 01/08/25
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: AnalystBenzinga • 01/06/25
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street AnalystsThe Motley Fool • 01/06/25
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?Zacks Investment Research • 01/02/25
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 12/31/24
Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone ElseInvestors Business Daily • 12/18/24
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030The Motley Fool • 12/16/24
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall StreetThe Motley Fool • 12/15/24
Viking Stock Pops, Then Drops On Latest Obesity / MASH Data - Why I'm Still BullishSeeking Alpha • 12/05/24
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?The Motley Fool • 12/03/24
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses MomentumBenzinga • 11/29/24